These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12078937)

  • 1. A post-marketing observational study to assess the safety of mibefradil in the community in England.
    Riley J; Wilton LV; Shakir SA
    Int J Clin Pharmacol Ther; 2002 Jun; 40(6):241-8. PubMed ID: 12078937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN; Wilton LV; Shakir SW
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
    Kasliwal R; Wilton LV; Shakir SA
    Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsades de pointes caused by Mibefradil.
    Gläser S; Steinbach M; Opitz C; Wruck U; Kleber FX
    Eur J Heart Fail; 2001 Oct; 3(5):627-30. PubMed ID: 11595612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan: a study of pharmacovigilance data on 14,522 patients.
    Mann R; Mackay F; Pearce G; Freemantle S; Wilton L
    J Hum Hypertens; 1999 Aug; 13(8):551-7. PubMed ID: 10455478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions of new active substances: mibefradil example.
    Krayenbühl JC; Vozeh S; Kondo-Oestreicher M; Dayer P
    Eur J Clin Pharmacol; 1999 Oct; 55(8):559-65. PubMed ID: 10541773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Clarke A; Wilton LV; Shakir SA
    Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.
    Ocran KW; Plauth M; Mai I; Lochs H
    Z Gastroenterol; 1999 Oct; 37(10):1025-8. PubMed ID: 10549098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
    Davies M; Wilton L; Shakir S
    Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: a pilot study of prescription-event monitoring in Japan.
    Samizo K; Kawabe E; Hinotsu S; Sato T; Kageyama S; Hamada C; Ohashi Y; Kubota K
    Drug Saf; 2002; 25(11):811-21. PubMed ID: 12222991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.